Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ — CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that…